Fill out the form below to the best of your abilities to be considered for the 2017 Lyfebulb-Novo Nordisk Innovation Summit & Award.
At this Summit, 10 selected Patient Entrepreneurs will have the opportunity to engage with Lyfebulb founders, Novo Nordisk Device R&D leadership, researchers and engineers, as well as venture capitalists
Lyfebulb and Novo Nordisk share a common ambition to stimulate high-impact innovation and to help patient entrepreneurs who have founded start-ups be successful. The Lyfebulb–Novo Nordisk Innovation Summit was built on the idea of the Lyfebulb Entrepreneur Circle, which was established in 2015, and features people who either have diabetes or have a close relative or loved one with the disease. They have created a product and/or a company based on issues encountered because of their personal experiences with diabetes. The first Lyfebulb-Novo Nordisk Innovation Summit took place in December of 2016, and the winner of the Award was Brianna Wolin.
The Innovation Summit will bring together Patient Entrepreneurs with venture capitalists, Lyfebulb founders, Novo Nordisk Device R&D leadership, researchers and engineers, in order to spotlight entrepreneurs’ efforts and ideas, and provide professional discussion, direction, and inspiration. This year the summit will give focus to innovations that disrupt the future of diabetes management.
3 DAYS TO CATALYZE INNOVATION
- Innovation Award
- Workshops & Discussions
- Behind the scenes of Novo Nordisk Device R&D
WHY DO PATIENT ENTREPRENEURS MATTER?
Patient Entrepreneurs have a unique ability to create value-adding disease management solutions beyond therapy. Our aim is to support patient-driven innovation and laser-focus on improving the quality of life for those living with diabetes.
BENEFITS OF THE LYFEBULB-NOVO NORDISK INNOVATION AWARD
Pitch Competition. The pitch competition brings to the stage emerging Patient Entrepreneurs to pitch their invention or idea to Lyfebulb founders, Novo Nordisk R&D device leadership, researchers and engineers, and venture capitalists. Contestants will respond to a round of Q&A by the judging panel. The top three outstanding Patient Entrepreneurs will receive monetary awards to further develop their ideas:
- 1st Prize: 25,000USD
- 2nd Prize: 15,000USD
- 3rd Prize: 10,000USD
National and international recognition:
Visibility of the selected 10 finalists and the winner in particular.
Invitation to the Lyfebulb–Novo Nordisk Innovation Summit 2017 in Copenhagen as one of 10 Finalists.
- Travel to and from, and accommodation in Copenhagen, Denmark during the Summit.
- Opportunity to engage with Lyfebulb founders, Novo Nordisk device research leadership, researchers and engineers, and venture capitalists to interact and discuss how together we can disrupt the future of the management of diabetes.
International Judging Panel. The winner will be chosen by a judging panel made up of international representatives from the diabetes community.
Are you the winner of the 2017 Lyfebulb–Novo Nordisk Innovation Award?
Summit & Award Judging Criteria
The Summit is open to Patient Entrepreneurs developing big ideas using consumer, medical devices and healthcare IT that disrupt the future management of diabetes
You are eligible for the 2017 Lyfebulb-Novo Nordisk Innovation Award if:
You work on innovative ideas and concepts for better management of diabetes using consumer or medical devices or healthcare IT (drug only innovations are excluded).
You live with diabetes or have a close relative and/or loved one with diabetes.
You have the aspiration to develop your project and to deliver the benefit to others suffering from the same burden.
You have a registered company for developing and commercializing your idea and concepts that the prize money can be award too.
You can document that there is a sound scientific and medical rationale for the idea.
You have a strong business case behind the idea.
Read our terms and conditions for the full eligibility criteria here.
The judging panel will look for evidence of:
Does the idea have potential to improve the lives of people with type 1 or type 2 diabetes?
In what aspect is the product/service unique in the market (not an altered marketed device) and does it meet other demands as well?
How is the idea truly disruptive for a different future for diabetes management?
Are the innovative and effective technologies scalable?
Ability to meet most of the healthcare related challenges (e.g. funding, regulations, requirements for clinical testing, etc.)
Team behind the project.
Achieving More, Together
Lyfebulb is a business focused on bridging patient communities with industry, and providing a strong voice to people living with chronic disease by empowering Patient Entrepreneurs. Our vision is to improve the quality of life of those living with diabetes and other chronic disease.
Lyfebulb was founded in 2014 and is headquartered in New York, NY.
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity.
Headquartered in Denmark, Novo Nordisk employs approximately 42,000 people in 77 countries and markets its products in more than 165 countries.